肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2014年
6期
394-396
,共3页
牛艳清%邓丽英%王云峰%余沙%吴九喜%皇甫娇阳
牛豔清%鄧麗英%王雲峰%餘沙%吳九喜%皇甫嬌暘
우염청%산려영%왕운봉%여사%오구희%황보교양
胃肿瘤%SOX2%免疫组织化学
胃腫瘤%SOX2%免疫組織化學
위종류%SOX2%면역조직화학
Stomach neoplasms%SOX2%Immunohistochemistry
目的 探讨转录因子SOX2在胃癌组织中的表达情况及其与临床病理特征的关系.方法 应用免疫组织化学技术检测67例胃癌组织中SOX2的表达,并选取30例远端切缘胃壁组织作为对照.结果 SOX2在胃癌组织中的阳性表达率为52.24%(35/67),显著低于对照组胃壁组织的阳性表达率93.33%(28/30),差异有统计学意义(x2=16.326,P< 0.01);在胃癌组织中SOX2的阳性表达率与肿瘤的分化程度、浸润深度、淋巴结转移以及临床分期有关,差异均有统计学意义(均P< 0.05).结论 SOX2表达下调与胃癌的早期发生有关,并与淋巴结转移及TNM分期密切相关,SOX2可作为预测胃癌预后的生物学指标.
目的 探討轉錄因子SOX2在胃癌組織中的錶達情況及其與臨床病理特徵的關繫.方法 應用免疫組織化學技術檢測67例胃癌組織中SOX2的錶達,併選取30例遠耑切緣胃壁組織作為對照.結果 SOX2在胃癌組織中的暘性錶達率為52.24%(35/67),顯著低于對照組胃壁組織的暘性錶達率93.33%(28/30),差異有統計學意義(x2=16.326,P< 0.01);在胃癌組織中SOX2的暘性錶達率與腫瘤的分化程度、浸潤深度、淋巴結轉移以及臨床分期有關,差異均有統計學意義(均P< 0.05).結論 SOX2錶達下調與胃癌的早期髮生有關,併與淋巴結轉移及TNM分期密切相關,SOX2可作為預測胃癌預後的生物學指標.
목적 탐토전록인자SOX2재위암조직중적표체정황급기여림상병리특정적관계.방법 응용면역조직화학기술검측67례위암조직중SOX2적표체,병선취30례원단절연위벽조직작위대조.결과 SOX2재위암조직중적양성표체솔위52.24%(35/67),현저저우대조조위벽조직적양성표체솔93.33%(28/30),차이유통계학의의(x2=16.326,P< 0.01);재위암조직중SOX2적양성표체솔여종류적분화정도、침윤심도、림파결전이이급림상분기유관,차이균유통계학의의(균P< 0.05).결론 SOX2표체하조여위암적조기발생유관,병여림파결전이급TNM분기밀절상관,SOX2가작위예측위암예후적생물학지표.
Objective To investigate the expression of SOX2 in gastric carcinoma and to analyze its relationship with clinicopathological features.Methods Immunohistochemistry method was used to detect the level of SOX2 in 67 cases of gastric carcinoma group and 30 cases of normal gastric mucosa group.Results The positive expression rate of SOX2 in gastric carcinoma group (52.24 %) was obviously lower than that in normal gastric mucosa group (93.33 %) (x2 =16.326,P < 0.01).The SOX2 expression was significantly correlated with differentiation,the depth of invasion,lymph node metastasis and TNM stage of the tumor (all P < 0.05).Conclusions The low expression of SOX2 may contribute to the early carcinogenesis of gastric carcinoma,and the expression level of SOX2 is closely related with lymph node metastasis and TNM stage.The expression level of SOX2 is a useful marker for predicting the prognosis of gastric carcinoma.